title: Off-label drug use as a consent and health regulation issue in New Zealand.
abstract: The term "off-label drug use" refers to drugs that have not yet acquired "approved" status or drugs that have acquired "approved" status but are used with a different dosage, route, or administration method other than that for which the drug has been approved. In New Zealand, the Medicines Act 1981 specifically allows for off-label drug use. However, this authority is limited by the Health and Disability Commissioner (Code of Health and Disability Services Consumers' Rights) Regulations 1996 and the common law, which require that off-label drug use is of an acceptable standard, that the patient should be fully informed, and that the patient should give informed consent. Off-label drug use is an important issue because the current law provides medical practitioners very wide discretionary power, without providing clarification for what is required of the practitioner in exercising his or her discretion in prescribing off-label. This paper discusses possible solutions to this issue, for example, establishing protocol for off-label use, an electronic database of off-label use, and the amendment of legal provisions.
authors.affiliation: University of Canterbury, Christchurch, 8041, New Zealand, rjc209@uclive.ac.nz.
authors.forename: Rebecca Julia
authors.initials: RJ
authors.lastname: Cook
mesh_terms: D033161:Government Regulation; D006801:Humans; D007258:Informed Consent; D009520:New Zealand; D056687:Off-Label Use / Q000331:legislation & jurisprudence*
references.citation: BMJ. 2000 Jan 8;320(7227):79-82
references.pmid: 10625257
references.citation: N Z Med J. 2011 Jun 10;124(1336):10-3
references.pmid: 21946739
references.citation: CMAJ. 2012 Mar 20;184(5):518
references.pmid: 22353585